Storys zum Thema Genetik

Schweizerischer Nationalfonds / Fonds national suisse

Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence

Merck Healthcare Germany

Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF ?-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; ...

Schweizerischer Nationalfonds / Fonds national suisse

Marie Heim-Vögtlin Prize 2018: Sara Montagner discovers the epigenetic secrets of mast cells

Bern (ots) - Epigenetic modifications of our DNA are a key aspect of the normal functioning of mast cells, which play an important role in immune reactions. Biologist Sara Montagner was able to demonstrate this in her work. She will receive this year's Marie Heim-Vögtlin Prize from the SNSF at the award ceremony in Bellinzona on 29 November 2018. Mast cells are white ...

Schweizerischer Nationalfonds / Fonds national suisse

A novel antibiotic from weeds

Researchers working on an SNSF project have discovered novel, antibiotically active chemical substances in a previously rarely explored site: the leaf of a common field weed. The just published findings show that this microcosm contains many still unknown natural products that could lead to new drugs. Many of the antibiotics used today were developed from natural products made by ...

Anima Biotech

Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets

Bernardsville, New Jersey (ots/PRNewswire) - Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform. (Logo: https://mma.prnewswire.com/media/721538/Anima_Biotech_Logo.jpg ...

Astellas Pharma Europe Limited

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...